Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

Evangelos Terpos,Ashraf Badros,Rakesh Popat,Paula Rodriguez-Otero,Asim V. Farooq,Bennie Jeng,Simona Degli Esposti,Eric Lewis,Ira Gupta,Joanna Opalinska,Antonio Palumbo,Suzanne Trudel

Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

2021

Evangelos Terpos
Ashraf Badros
Rakesh Popat
Paula Rodriguez-Otero
Asim V. Farooq
Bennie Jeng
Simona Degli Esposti
Eric Lewis
Ira Gupta
Joanna Opalinska
Antonio Palumbo
Suzanne Trudel

8033Background: Belantamab mafodotin (GSK2857916; belamaf; BLENREP) is a B-cell maturation antigen (BCMA)-targeting antibody–drug conjugate approved in the US and EU as a monotherapy for the treatm...

Keywords:

Medicine
in patient
Ophthalmology
best corrected visual acuity
Refractory Multiple Myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations